Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib
Posted by Adam Awdish on
Rabbit Anti Mouse Antiplasmin Polyclonal Fractionated HRP Labeled from Innovative Research was used in the following study:
Yusuke Yamashita, Shuhei Morita, Hiroki Hosoi, Hiroshi Kobata, Shohei Kishimoto, Tatsuya Ishibashi, Hiroyuki Mishima, Akira Kinoshita, Bradley J. Backes, Koh-Ichiro Yoshiura, Feroz R. Papa, Takashi Sonoki, and Shinobu Tamura
International Journal of Molecular Sciences
August 31, 2020
Inositol-requiring enzyme 1α (IRE1α) and protein kinase R-like endoplasmic reticulum kinase (PERK) are key regulators of the unfolded protein response (UPR). The UPR is a cellular mechanism that helps ensure unfolded proteins do not leave the endoplasmic reticulum of a cell. Recent discoveries have shown that kinase-inhibiting RNase attenuator 6 (KIRA6), an IRE1α inhibitor, showed potential for use as a treatment against multiple myeloma (MM). Researchers in this study analyzed the treatment potential of combining KIRA8 and nilotinib, an existing drug approved by the FDA, for use in fighting myeloma.
Related products available from Innovative Research also include:
Rabbit Anti Mouse IgG Polyclonal Affinity Purified